BMC Pregnancy Childbirth 21 , 51 (2021)
The impact of CRISPR-cas9 on age-related disorders: from pathology to therapy
PubMed, 2024 Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults British Journal of Pharmacology, 2025 Consuming more protein may protect patients taking an anti-obesity drug from muscle loss Endocrine Society, ENDO 2025 Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss Mass General Advances in Motion GLP-1s and Lean Mass: What the Research Shows ACE Certified, June 2025 New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation American Diabetes Association, 2025 Impact of GLP-1 Receptor Agonist Therapy in Patients at High Risk for Sarcopenia Current Nutrition Reports, Springer, 2025
Further, whilst real barriers persist, available evidence has indeed corroborated the potential clinical utility of GLP-1 RAs in HF(5), with the most recent GLP-1 RA CVOT (Amplitude-O with once-weekly efpeglenatide) indicating a relative risk reduction for hospitalisation-requiring HF of at least 30% in people with type 2 diabetes (Gerstein et al., 2021)
